OCULAR THERAPEUTIX, INCOCUL
Market cap
$2.3B
P/E ratio
| Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | |
| Product revenue, net | - | - | - | - | - | - | - | - | 50 | 58 | 63 |
| Collaboration revenue | - | - | - | - | - | - | - | - | 1 | 1 | 0 |
| Total revenue, net | - | - | - | - | - | 4 | 17 | 44 | 51 | 58 | 64 |
| Cost of Revenue | - | - | - | - | - | 2 | 2 | 4 | 5 | 5 | 6 |
| Research and development | 19 | 27 | 27 | 31 | 37 | 41 | 29 | 50 | 53 | 61 | 128 |
| Selling and marketing | 2 | 4 | 7 | 17 | 5 | 24 | 27 | 35 | 40 | 41 | 42 |
| General and administrative | 7 | 9 | 11 | 16 | 19 | 22 | 23 | 32 | 32 | 34 | 61 |
| Total costs and operating expenses | - | - | 45 | 64 | 61 | 90 | 80 | 122 | 130 | 141 | 236 |
| Loss from operations | -27 | -38 | -43 | -62 | -59 | -86 | -63 | -78 | -79 | -82 | -172 |
| Interest income | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 4 | 20 |
| Interest expense | - | - | - | - | - | - | - | - | - | - | 14 |
| Change in fair value of derivative liabilities | - | - | - | - | - | - | - | - | - | -5 | -0 |
| Gain (Loss) on Extinguishment of Debt | -0 | - | - | - | - | - | - | - | - | 14 | -28 |
| Other expense | -0 | 0 | -0 | 0 | - | -0 | - | 0 | -0 | -0 | - |
| Total other income (expense), net | -2 | -2 | -1 | -1 | -1 | -1 | -93 | 71 | 8 | 2 | -22 |
| Net loss | -29 | -40 | -45 | -63 | -60 | 86 | -156 | -7 | -71 | -81 | -194 |
| Earnings Per Share, Basic | - | - | - | - | - | - | - | -0.09 | -0.92 | -1.01 | -1.22 |
| Earnings Per Share, Diluted | - | - | - | - | - | - | - | -0.98 | -0.97 | -1.02 | -1.22 |